CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan

NCT00562419 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Brain and Central Nervous System Tumors
Recurrent Glioblastoma Multiforme

Interventions

DRUG: CT-322
DRUG: irinotecan hydrochloride

Sponsor

Adnexus, A Bristol-Myers Squibb R&D Company